Neoadjuvant therapies are increasingly used for gastric adenocarcinoma.

A significant increase in the utilization of neoadjuvant therapies, particularly neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NCRT), was observed from 2012 to 2017 among gastric adenocarcinoma patients. The analysis included 25,073 patients, revealing median overall survival rates of 51.0 months for those receiving neoadjuvant therapy versus 42.4 months for adjuvant therapy and 38.0 months for surgery only. Disparities in treatment access were noted among Black patients and those from lower-income backgrounds.